Management of Radiation Proctitis

Introduction to Radiation Proctitis

The American Society for Gastrointestinal Endoscopy recommends argon plasma coagulation (APC) as the first-line endoscopic treatment for mild-to-moderate bleeding radiation proctitis, with sucralfate enemas recommended for chronic bleeding when endoscopic therapy is not immediately available or as adjunctive therapy 1, 2, 3

Acute radiation proctitis typically presents with diarrhea, cramps, tenesmus, urgency, and minor bleeding that usually resolves spontaneously after treatment completion, according to the European Society for Radiotherapy and Oncology 4
Chronic radiation proctitis is characterized by telangiectasias, bleeding, and potential complications including strictures, perforation, or fistula formation, as described by the European Society for Radiotherapy and Oncology 4

For mild-to-moderate disease, the American College of Gastroenterology recommends endoscopic thermal therapy as the primary treatment approach, with argon plasma coagulation (APC) being the preferred modality due to its non-contact technique and ability to treat large surface areas safely on an outpatient basis 1, 2, 5
Alternative endoscopic options include heater probe or bipolar electrocoagulation, which significantly decrease severe bleeding and improve quality of life at 6 months, according to the American College of Gastroenterology 1, 2, 5

The European Society for Medical Oncology (ESMO) recommends sucralfate enemas as the primary medical treatment for chronic radiation-induced proctitis with rectal bleeding, with a dosage of 2 grams sucralfate mixed with 30-50 mL water administered twice daily initially 6, 7, 3
Patients should roll through 360 degrees to coat the entire rectal surface and retain the enema for at least 20 minutes, as suggested by the European Society for Medical Oncology (ESMO) 3

The American Society for Therapeutic Radiology and Oncology recommends radiation technique optimization, including IMRT/IGRT, to significantly reduce rectal toxicity compared to 3D-CRT 4
The European Society for Medical Oncology (ESMO) suggests intrarectal amifostine (≥340 mg/m²) to prevent radiation proctitis in patients receiving standard-dose radiotherapy for rectal cancer 6, 7

Short-term complications of APC include anorectal pain, tenesmus, and abdominal distention, according to the American College of Gastroenterology 1, 2
Long-term complications of APC include chronic rectal ulcer, rectal stricture, and persistent anorectal pain, as described by the American College of Gastroenterology 1, 2
Risk factors for worse outcomes include diabetes mellitus, vascular disease, arterial hypertension, atherosclerosis, inflammatory bowel disease, collagen disease, and HIV infection, according to the European Society for Radiotherapy and Oncology 4